Search research articles
Contact Us
Filters
Showing results (191-200 of 243) with videos related to
Page
of 25
Sort By:
Nature Cancer
|
June 4, 2026
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial
Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials
Marijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology
|
April 11, 2022
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
Marijke B Coomans, Linda Dirven, Neil Aaronson, et al.
Nature Communications
|
May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
Frank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neuro-Oncology
|
November 5, 2019
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 10, 2024
Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy
Julian P Layer, Ehab Shiban, Stefanie Brehmer, et al.
International Journal of Cancer
|
October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial
Theophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology
|
September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Johannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Neuro-Oncology Practice
|
December 11, 2020
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients
Marijke B Coomans, Martin J B Taphoorn, Neil K Aaronson, et al.
In Vivo (Athens, Greece)
|
October 30, 2025
Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in Germany
Johanna Ernst, Katharina Alfter, Alexander Mustea, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 243) with videos related to
Sort By:
Page
of 25
Nature Cancer
|
June 4, 2026
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial
Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials
Marijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology
|
April 11, 2022
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
Marijke B Coomans, Linda Dirven, Neil Aaronson, et al.
Nature Communications
|
May 28, 2024
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
Frank A Giordano, Julian P Layer, Sonia Leonardelli, et al.
Neuro-Oncology
|
November 5, 2019
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 10, 2024
Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy
Julian P Layer, Ehab Shiban, Stefanie Brehmer, et al.
International Journal of Cancer
|
October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial
Theophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology
|
September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
Johannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Neuro-Oncology Practice
|
December 11, 2020
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients
Marijke B Coomans, Martin J B Taphoorn, Neil K Aaronson, et al.
In Vivo (Athens, Greece)
|
October 30, 2025
Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in Germany
Johanna Ernst, Katharina Alfter, Alexander Mustea, et al.
Page
of 25